RAC 0.63% $1.59 race oncology ltd

General Comments / Chat, page-11426

  1. 2,775 Posts.
    lightbulb Created with Sketch. 10630
    Not that it matters now, but the August 2023 plan didn't collect any CP data until the 2030s. It was purely focused on anticancer activity until Phase 3.

    You are right that AML will be running behind the CPACS trial and that it won't treat the first patient until H1 2025.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.